MX2017007381A - Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. - Google Patents
Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.Info
- Publication number
- MX2017007381A MX2017007381A MX2017007381A MX2017007381A MX2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A
- Authority
- MX
- Mexico
- Prior art keywords
- maf
- binding members
- human
- bind
- determination
- Prior art date
Links
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 title 1
- 102000049425 human MAF Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090599P | 2014-12-11 | 2014-12-11 | |
| PCT/IB2015/059562 WO2016092524A1 (en) | 2014-12-11 | 2015-12-11 | Binding members for human c-maf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007381A true MX2017007381A (es) | 2017-11-06 |
Family
ID=55024191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007381A MX2017007381A (es) | 2014-12-11 | 2015-12-11 | Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10793642B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3229909B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017538412A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170093182A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107001480B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015358868A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017012515A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2967224C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017007381A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016092524A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3901283T3 (da) | 2016-05-25 | 2025-09-15 | Inbiomotion Sl | Terapeutisk behandling af brystkræft baseret på c-maf-status |
| MX2020005182A (es) | 2017-11-22 | 2020-08-17 | Inbiomotion Sl | Tratamiento terapeutico del cancer de mama basado en el estado del c-maf. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9509957D0 (en) | 1995-05-17 | 1995-07-12 | Khalil Nasreen | Post-translational activation of tgf-1 involving the tsp-1 receptor cd36 |
| US5814468A (en) | 1996-03-27 | 1998-09-29 | Coulter International Corp. | Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution |
| US5958671A (en) | 1996-04-23 | 1999-09-28 | Presidents And Fellows Of Harvard College | Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
| US6017729A (en) | 1996-12-23 | 2000-01-25 | Immunex Corporation | Receptor activator of NF-κB |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| EP1178958B1 (en) | 1999-03-15 | 2004-02-18 | Axys Pharmaceuticals, Inc. | N-cyanomethyl amides as protease inhibitors |
| EP1248612B1 (en) | 2000-01-06 | 2008-02-27 | Merck Frosst Canada Ltd. | Novel compounds and compositions as protease inhibitors |
| JP2004505611A (ja) | 2000-04-03 | 2004-02-26 | コリクサ コーポレイション | 乳癌の検出およびモニタリングのための方法、組成物、およびキット |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| NO345566B1 (no) | 2001-06-26 | 2021-04-19 | Amgen Inc | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| US7741077B2 (en) | 2001-12-22 | 2010-06-22 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| JP5457673B2 (ja) | 2005-09-20 | 2014-04-02 | ベリデックス・リミテッド・ライアビリティ・カンパニー | ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用 |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US8785150B2 (en) | 2006-06-30 | 2014-07-22 | University Of Southern California | Quantifiable internal reference standards for immunohistochemistry and uses thereof |
| WO2008086800A2 (en) | 2007-01-15 | 2008-07-24 | Aarhus Universitet | Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16 |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| CA2676791A1 (en) | 2007-02-16 | 2008-11-06 | Pacific Arrow Limited | Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof |
| EP2152747B1 (en) | 2007-05-24 | 2018-01-03 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| EP2412825B8 (en) | 2009-03-24 | 2018-01-10 | Riken | Leukemia stem cell markers |
| WO2011039734A2 (en) | 2009-10-02 | 2011-04-07 | Enzo Medico | Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer |
| US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2671076A4 (en) | 2011-02-04 | 2016-11-16 | Bioarray Genetics Inc | METHODS OF USING GENE EXPRESSION SIGNATURES FOR SELECTING A TREATMENT METHOD, PREDICTING PROGNOSIS, SURVIVAL, AND / OR PREDICTING A RESPONSE TO TREATMENT |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| EP2971113B1 (en) | 2013-03-15 | 2020-08-12 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| KR20160061424A (ko) | 2013-10-09 | 2016-05-31 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3901283T3 (da) | 2016-05-25 | 2025-09-15 | Inbiomotion Sl | Terapeutisk behandling af brystkræft baseret på c-maf-status |
| MX2020005182A (es) | 2017-11-22 | 2020-08-17 | Inbiomotion Sl | Tratamiento terapeutico del cancer de mama basado en el estado del c-maf. |
-
2015
- 2015-12-11 CA CA2967224A patent/CA2967224C/en active Active
- 2015-12-11 AU AU2015358868A patent/AU2015358868A1/en not_active Abandoned
- 2015-12-11 MX MX2017007381A patent/MX2017007381A/es unknown
- 2015-12-11 WO PCT/IB2015/059562 patent/WO2016092524A1/en not_active Ceased
- 2015-12-11 JP JP2017530686A patent/JP2017538412A/ja active Pending
- 2015-12-11 KR KR1020177018132A patent/KR20170093182A/ko not_active Withdrawn
- 2015-12-11 EP EP15816535.7A patent/EP3229909B1/en active Active
- 2015-12-11 US US15/534,893 patent/US10793642B2/en active Active
- 2015-12-11 BR BR112017012515A patent/BR112017012515A2/pt not_active Application Discontinuation
- 2015-12-11 CN CN201580067068.4A patent/CN107001480B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107001480B (zh) | 2021-12-03 |
| KR20170093182A (ko) | 2017-08-14 |
| CN107001480A (zh) | 2017-08-01 |
| WO2016092524A1 (en) | 2016-06-16 |
| EP3229909A1 (en) | 2017-10-18 |
| JP2017538412A (ja) | 2017-12-28 |
| AU2015358868A1 (en) | 2017-06-01 |
| BR112017012515A2 (pt) | 2018-01-02 |
| CA2967224C (en) | 2023-08-22 |
| CA2967224A1 (en) | 2016-06-16 |
| US10793642B2 (en) | 2020-10-06 |
| EP3229909B1 (en) | 2020-10-14 |
| US20170369589A1 (en) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274370A (en) | Single-region antibodies that bind CD137 | |
| CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
| IL256848A (en) | Antibody molecules that bind cd45 | |
| PH12017502180A1 (en) | Tau-binding antibodies | |
| MX2017007381A (es) | Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| ZA201801391B (en) | Antigen binding constructs to target molecules | |
| PH12016501763A1 (en) | Multispecific antibodies | |
| EA202092435A2 (ru) | Моноклональные антитела против bcma | |
| LT3169706T (lt) | Antikūnai, besirišantys prie axl | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| MY193677A (en) | Tau-binding antibodies | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| IL256853A (en) | antibody molecules that bind cd79 | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| MX2016016883A (es) | Anticuerpo anti-axl. | |
| LT3166970T (lt) | Patobulinti a-beta protofibriles surišantys antikūnai | |
| MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
| PL3200822T3 (pl) | Cząsteczki wiążące, zwłaszcza przeciwciała, które wiążą się z l1cam (cd171) | |
| SG10201806454RA (en) | Anti-tenascin c antibodies and uses thereof | |
| EP3131580A4 (en) | Antibody therapeutics that bind cd147 |